The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors； the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.so de una cantidad terapéuticamente efectiva de dianhidrogalactitol DAG o un derivado del mismo, CARACTERIZADO porque sirve para preparar un medicamento útil para el tratamiento del carcinoma de pulmón de células no pequeñas NSCLC resistente a un agente quimioterapéutico que contiene platino.
